Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
16
CCRN Quote, Financials, Valuation and Earnings
Last price:
$8.21
Seasonality move
:
-9.75%
Day range:
$8.00 - $8.35
52-week range:
$7.43 - $18.30
Dividend yield:
0%
P/E ratio:
64.87x
P/S ratio:
0.24x
P/B ratio:
0.66x
Volume:
560.7K
Avg. volume:
1.3M
1-year change:
-54.82%
Market cap:
$269.9M
Revenue:
$1.3B
EPS (TTM):
-$0.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CCRN
Cross Country Healthcare, Inc.
|
$256.7M | $0.01 | -17.95% | -48.25% | $9.66 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
HUM
Humana, Inc.
|
$35.5B | $10.69 | 10.49% | 3.85% | $288.42 |
|
IGC
IGC Pharma, Inc.
|
$198K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CCRN
Cross Country Healthcare, Inc.
|
$8.24 | $9.66 | $269.9M | 64.87x | $0.00 | 0% | 0.24x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$5.48 | $42.50 | $16.6M | -- | $0.00 | 0% | -- |
|
HUM
Humana, Inc.
|
$276.85 | $288.42 | $33.3B | 25.95x | $0.89 | 1.28% | 0.26x |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.54x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CCRN
Cross Country Healthcare, Inc.
|
0.54% | 1.473 | 0.48% | 3.37x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
HUM
Humana, Inc.
|
40.5% | 0.178 | 40.21% | 0.00x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.713 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CCRN
Cross Country Healthcare, Inc.
|
$46.8M | $806K | -3.74% | -3.76% | 0.32% | $17.9M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
HUM
Humana, Inc.
|
-- | $400M | 4.25% | 7.3% | 0.41% | $836M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
Cross Country Healthcare, Inc. vs. Competitors
-
Which has Higher Returns CCRN or AIM?
AIM ImmunoTech has a net margin of -1.91% compared to Cross Country Healthcare, Inc.'s net margin of -10571.43%. Cross Country Healthcare, Inc.'s return on equity of -3.76% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital CCRNCross Country Healthcare, Inc.18.73% -$0.15 $410.3M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About CCRN or AIM?
Cross Country Healthcare, Inc. has a consensus price target of $9.66, signalling upside risk potential of 17.26%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Cross Country Healthcare, Inc., analysts believe AIM ImmunoTech is more attractive than Cross Country Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCRNCross Country Healthcare, Inc.0 7 0 AIMAIM ImmunoTech1 0 0 -
Is CCRN or AIM More Risky?
Cross Country Healthcare, Inc. has a beta of 0.446, which suggesting that the stock is 55.421% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock CCRN or AIM?
Cross Country Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cross Country Healthcare, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCRN or AIM?
Cross Country Healthcare, Inc. quarterly revenues are $250.1M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Cross Country Healthcare, Inc.'s net income of -$4.8M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Cross Country Healthcare, Inc.'s price-to-earnings ratio is 64.87x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cross Country Healthcare, Inc. is 0.24x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCRNCross Country Healthcare, Inc.0.24x 64.87x $250.1M -$4.8M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns CCRN or CVM?
CEL-SCI Corp. has a net margin of -1.91% compared to Cross Country Healthcare, Inc.'s net margin of --. Cross Country Healthcare, Inc.'s return on equity of -3.76% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital CCRNCross Country Healthcare, Inc.18.73% -$0.15 $410.3M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About CCRN or CVM?
Cross Country Healthcare, Inc. has a consensus price target of $9.66, signalling upside risk potential of 17.26%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 675.55%. Given that CEL-SCI Corp. has higher upside potential than Cross Country Healthcare, Inc., analysts believe CEL-SCI Corp. is more attractive than Cross Country Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCRNCross Country Healthcare, Inc.0 7 0 CVMCEL-SCI Corp.1 0 0 -
Is CCRN or CVM More Risky?
Cross Country Healthcare, Inc. has a beta of 0.446, which suggesting that the stock is 55.421% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock CCRN or CVM?
Cross Country Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cross Country Healthcare, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCRN or CVM?
Cross Country Healthcare, Inc. quarterly revenues are $250.1M, which are larger than CEL-SCI Corp. quarterly revenues of --. Cross Country Healthcare, Inc.'s net income of -$4.8M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, Cross Country Healthcare, Inc.'s price-to-earnings ratio is 64.87x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cross Country Healthcare, Inc. is 0.24x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCRNCross Country Healthcare, Inc.0.24x 64.87x $250.1M -$4.8M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns CCRN or HUM?
Humana, Inc. has a net margin of -1.91% compared to Cross Country Healthcare, Inc.'s net margin of 0.59%. Cross Country Healthcare, Inc.'s return on equity of -3.76% beat Humana, Inc.'s return on equity of 7.3%.
Company Gross Margin Earnings Per Share Invested Capital CCRNCross Country Healthcare, Inc.18.73% -$0.15 $410.3M HUMHumana, Inc.-- $1.62 $31.2B -
What do Analysts Say About CCRN or HUM?
Cross Country Healthcare, Inc. has a consensus price target of $9.66, signalling upside risk potential of 17.26%. On the other hand Humana, Inc. has an analysts' consensus of $288.42 which suggests that it could grow by 4.18%. Given that Cross Country Healthcare, Inc. has higher upside potential than Humana, Inc., analysts believe Cross Country Healthcare, Inc. is more attractive than Humana, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCRNCross Country Healthcare, Inc.0 7 0 HUMHumana, Inc.6 17 1 -
Is CCRN or HUM More Risky?
Cross Country Healthcare, Inc. has a beta of 0.446, which suggesting that the stock is 55.421% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.811%.
-
Which is a Better Dividend Stock CCRN or HUM?
Cross Country Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.28% to investors and pays a quarterly dividend of $0.89 per share. Cross Country Healthcare, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CCRN or HUM?
Cross Country Healthcare, Inc. quarterly revenues are $250.1M, which are smaller than Humana, Inc. quarterly revenues of $32.6B. Cross Country Healthcare, Inc.'s net income of -$4.8M is lower than Humana, Inc.'s net income of $194M. Notably, Cross Country Healthcare, Inc.'s price-to-earnings ratio is 64.87x while Humana, Inc.'s PE ratio is 25.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cross Country Healthcare, Inc. is 0.24x versus 0.26x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCRNCross Country Healthcare, Inc.0.24x 64.87x $250.1M -$4.8M HUMHumana, Inc.0.26x 25.95x $32.6B $194M
-
Which has Higher Returns CCRN or IGC?
IGC Pharma, Inc. has a net margin of -1.91% compared to Cross Country Healthcare, Inc.'s net margin of -953.4%. Cross Country Healthcare, Inc.'s return on equity of -3.76% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital CCRNCross Country Healthcare, Inc.18.73% -$0.15 $410.3M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About CCRN or IGC?
Cross Country Healthcare, Inc. has a consensus price target of $9.66, signalling upside risk potential of 17.26%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1190.38%. Given that IGC Pharma, Inc. has higher upside potential than Cross Country Healthcare, Inc., analysts believe IGC Pharma, Inc. is more attractive than Cross Country Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCRNCross Country Healthcare, Inc.0 7 0 IGCIGC Pharma, Inc.2 0 0 -
Is CCRN or IGC More Risky?
Cross Country Healthcare, Inc. has a beta of 0.446, which suggesting that the stock is 55.421% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.78%.
-
Which is a Better Dividend Stock CCRN or IGC?
Cross Country Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cross Country Healthcare, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCRN or IGC?
Cross Country Healthcare, Inc. quarterly revenues are $250.1M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Cross Country Healthcare, Inc.'s net income of -$4.8M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Cross Country Healthcare, Inc.'s price-to-earnings ratio is 64.87x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cross Country Healthcare, Inc. is 0.24x versus 22.54x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCRNCross Country Healthcare, Inc.0.24x 64.87x $250.1M -$4.8M IGCIGC Pharma, Inc.22.54x -- $191K -$1.8M
-
Which has Higher Returns CCRN or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -1.91% compared to Cross Country Healthcare, Inc.'s net margin of -255.85%. Cross Country Healthcare, Inc.'s return on equity of -3.76% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CCRNCross Country Healthcare, Inc.18.73% -$0.15 $410.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CCRN or NBY?
Cross Country Healthcare, Inc. has a consensus price target of $9.66, signalling upside risk potential of 17.26%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Cross Country Healthcare, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cross Country Healthcare, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCRNCross Country Healthcare, Inc.0 7 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CCRN or NBY More Risky?
Cross Country Healthcare, Inc. has a beta of 0.446, which suggesting that the stock is 55.421% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock CCRN or NBY?
Cross Country Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cross Country Healthcare, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCRN or NBY?
Cross Country Healthcare, Inc. quarterly revenues are $250.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cross Country Healthcare, Inc.'s net income of -$4.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cross Country Healthcare, Inc.'s price-to-earnings ratio is 64.87x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cross Country Healthcare, Inc. is 0.24x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCRNCross Country Healthcare, Inc.0.24x 64.87x $250.1M -$4.8M NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
